Clinical protocols for the treatment of gastrointestinal cancer

$431,019ZIAFY2021CANIH

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Paper 38989414 Paper 38205877 Paper 38184304 Paper 38124450 Paper 37428789 Paper 37081117 Paper 36932227 Paper 36754451 Paper 36697706 Paper 35378172 Paper 35274717 Paper 34340996 Paper 33811727 Paper 33510460 Paper 33397682 Paper 32430997 Paper 31996388 Paper 30830521 Paper 30527657 Paper 30377451 Paper 30287171 Paper 29959458 Paper 29909986 Paper 29904153 Paper 29798856 Paper 29602801 Paper 29427558 Paper 29248746 Paper 29230285 Paper 29157287 Paper 29150490 Paper 29136500 Paper 29066575 Paper 28923358 Paper 28877549 Paper 28857485 Paper 28738021 Paper 28605745 Paper 28596308 Paper 28480899 Paper 28468006 Paper 28465443 Paper 28331613 Paper 28174418 Paper 28167218 Paper 27816492 Paper 27803114 Paper 27214394 Paper 27206802 Paper 27194579 Paper 27177447 Paper 26998818 Paper 26666244 Paper 26535124 Paper 25685318 Paper 25584002 Paper 24996116 Paper 24917983 Paper 24852116 Paper 24622679 Paper 24287277 Paper 24243572 Paper 23885909 Paper 23708586 Paper 23670093 Paper 23169292 Paper 23112096 Paper 22930464 Paper 22773551 Paper 22655277

Abstract

Gastrointestinal cancer represents one of the major reasons for tumor related death in the United States. Current treatment options are limited to surgery, chemotherapy, radiation therapy and molecular targeted therapy and new treatment options are urgently needed. We have been enrolling patients on the following protocols:NCI-20-C-0022: Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC). NCI-19-C-0033:Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers; NCI-17-C-0092: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer; NCI-16-C-0135: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) ;.19C0094 A: A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC).

View original record on NIH RePORTER →